

Christine Sekaggya-Wiltshire

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2034661/publications.pdf>

Version: 2024-02-01

36
papers

362
citations

932766

10
h-index

940134

16
g-index

42
all docs

42
docs citations

42
times ranked

609
citing authors

#	ARTICLE	IF	CITATIONS
1	Stable warfarin dose prediction in sub-Saharan African patients: A machine learning approach and external validation of a clinical dose initiation algorithm. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 20-29.	1.3	10
2	Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda. <i>Mycoses</i> , 2022, 65, 625-634.	1.8	10
3	Developing and Validating a Clinical Warfarin Dose Initiation Model for Black African Patients in South Africa and Uganda. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1564-1574.	2.3	8
4	MicroRNA-122 and cytokeratin-18 have potential as biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3206-3217.	1.1	14
5	“Out of sight, out of mind?” A follow-up on HIV-infected patients with drug-resistant pulmonary tuberculosis in Uganda: A case series. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110197.	0.2	0
6	Anticoagulation in sub-Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3699-3705.	1.1	12
7	Internal Medicine Clerkship Amidst COVID-19 Pandemic: A Cross-Sectional Study of the Clinical Learning Experience of Undergraduate Medical Students at Makerere University, Uganda. <i>Advances in Medical Education and Practice</i> , 2021, Volume 12, 253-262.	0.7	11
8	Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3056-3068.	1.1	13
9	Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study. <i>BMC Infectious Diseases</i> , 2021, 21, 513.	1.3	4
10	Genetic factors associated with tuberculosis-related clinical outcomes in HIV-infected Black African patients: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2021, 22, 997-1017.	0.6	0
11	Optimal therapy for multidrug-resistant tuberculosis and HIV. <i>Lancet, The</i> , 2020, 396, 363-365.	6.3	0
12	Pharmacokinetics, Safety/tolerability, and Efficacy of high-dose Rifampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). <i>Trials</i> , 2020, 21, 181.	0.7	14
13	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. <i>PLoS ONE</i> , 2020, 15, e0227458.	1.1	25
14	Utility of the monocyte to lymphocyte ratio in diagnosing latent tuberculosis among HIV-infected individuals with a negative tuberculosis symptom screen. <i>PLoS ONE</i> , 2020, 15, e0241786.	1.1	6
15	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
16	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
17	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
18	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0

#	ARTICLE	IF	CITATIONS
19	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
20	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
21	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. Journal of Antimicrobial Chemotherapy, 2019, 74, 135-138.	1.3	7
22	Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 615-618.	1.5	6
23	Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	11
24	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. Open Forum Infectious Diseases, 2019, 6, ofz035.	0.4	5
25	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clinical Pharmacology and Therapeutics, 2019, 106, 450-457.	2.3	13
26	Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 481-487.	0.9	2
27	Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study. AIDS Research and Therapy, 2019, 16, 39.	0.7	5
28	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Journal of Antimicrobial Chemotherapy, 2019, 74, 468-472.	1.3	9
29	Delayed Sputum Culture Conversion in Tuberculosisâ€“Human Immunodeficiency Virusâ€“Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clinical Infectious Diseases, 2018, 67, 708-716.	2.9	34
30	The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. Tuberculosis, 2018, 108, 77-82.	0.8	14
31	Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort. PLoS ONE, 2018, 13, e0206796.	1.1	30
32	HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 566-573.	0.9	14
33	Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. AIDS Research and Therapy, 2017, 14, 1.	0.7	37
34	Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the XpertÂ® MTB/RIF era: a cohort study. BMC Infectious Diseases, 2017, 17, 433.	1.3	10
35	Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. BMJ Open, 2017, 7, e014679.	0.8	9
36	Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis. BMC Pulmonary Medicine, 2017, 17, 149.	0.8	28